Yifan Wang

Yifan Wang

Auto-generated profile, based on publicly available information

Yifan Wang

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
Zhaogang YangZhaogang Yang
Zhaogang Yang
JSJunfeng Shi
Junfeng Shi
JXJing Xie
Jing Xie
YWYifan Wang
Yifan Wang
JSJingyao Sun
Jingyao Sun
LLL. James Lee
L. James Lee

5 March 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YWYifan Wang
Yifan Wang
WDWeiye Deng
Weiye Deng
NLNan Li
Nan Li
SNShinya Neri
Shinya Neri
ASAmrish Sharma
Amrish Sharma
SLSteven Lin
Steven Lin
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the development of anticancer immunotherapy agents has thrived. The success of many immune-checkpoint inhibitors has drastically changed the landscape of cancer treatment. For some types of cancer, monotherapy for targeting immune checkpoint pathways has proven more effective than traditional therapies, and combining immunotherapy with current treatment strategies may yield even better outcomes. Numerous preclinical studies have suggested that combining immunotherapy with radiotherapy could be a promising strategy for synergistic enhancement of treatment efficacy. Radiation delivered to the tumor site affects both tumor cells and surrounding stromal cells. Radiation-induced cancer cell damage exposes tumor-specific antigens that make them visible to immune surveillance and promotes the priming and activation of cytotoxic T cells. Radiation-induced modulation of the tumor microenvironment may also facilitate the recruitment and infiltration of immune cells. This unique relationship is the rationale for combining radiation with immune checkpoint blockade. Enhanced tumor recognition and immune cell targeting with checkpoint blockade may unleash the immune system to eliminate the cancer cells. However, challenges remain to be addressed to maximize the efficacy of this promising combination. Here we summarize the mechanisms of radiation and immune system interaction, and we discuss current challenges in radiation and immune checkpoint blockade therapy and possible future approaches to boost this combination.

12 January 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YYYi You
Yi You
YTYu Tian
Yu Tian
Zhaogang YangZhaogang Yang
Zhaogang Yang
JSJunfeng Shi
Junfeng Shi
KKKwang Joo Kwak
Kwang Joo Kwak
ALAndrew S. Lee
Andrew S. Lee

20 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CRChristina A. von Roemeling
Christina A. von Roemeling
YWYifan Wang
Yifan Wang
YQYaqing Qie
Yaqing Qie
HYHengfeng Yuan
Hengfeng Yuan
HZHai Zhao
Hai Zhao
BKBetty Y. S. Kim
Betty Y. S. Kim
Tumour cell phagocytosis by antigen presenting cells (APCs) is critical to the generation of antitumour immunity. However, cancer cells can evade phagocytosis by upregulating anti-phagocytosis molecule CD47. Here, we show that CD47 blockade alone is inefficient in stimulating glioma cell phagocytosis. However, combining CD47 blockade with temozolomide results in a significant pro-phagocytosis effect due to the latter’s ability to induce endoplasmic reticulum stress response. Increased tumour cell phagocytosis subsequently enhances antigen cross-presentation and activation of cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS–STING) in APCs, resulting in more efficient T cell priming. This bridging of innate and adaptive responses inhibits glioma growth, but also activates immune checkpoint. Sequential administration of an anti-PD1 antibody overcomes this potential adaptive resistance. Together, these findings reveal a dynamic relationship between innate and adaptive immune regulation in tumours and support further investigation of phagocytosis modulation as a strategy to enhance cancer immunotherapy responses.

30 May 2022 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
XLXuefeng Li
Xuefeng Li
SKSina Khorsandi
Sina Khorsandi
YWYifan Wang
Yifan Wang
JSJulien Santelli
Julien Santelli
KHKristin Huntoon
Kristin Huntoon
Jacques LuxJacques Lux
Jacques Lux

15 March 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YWYifan Wang
Yifan Wang
ZLZhi-Gang Liu
Zhi-Gang Liu
HYHengfeng Yuan
Hengfeng Yuan
WDWeiye Deng
Weiye Deng
JLJing Li
Jing Li
WJWen Jiang
Wen Jiang
The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.